Margaret Patrick
Margaret Patrick joined Market Realist in September 2014 and has written close to 3,000 articles. She has covered the healthcare sector, which includes pharmaceutical and biotechnology companies, medical device companies, health insurance companies, and hospital companies. Currently, she is following the cannabis sector.
Prior to joining Market Realist, Margaret worked as equity and data analyst at MSCI for a year and as a financial research analyst at Deloitte for two years. She completed her MBA with finance specialization in 2011. She also passed all three CFA levels.
Besides writing on stocks, Margaret loves to read about nutrition, culture, and mythology. She's also fond of traveling to new places.
Disclosure: I am in full compliance with all ethics and other policies for Market Realist research analysts. I am not invested in securities that I cover on Market Realist.
More From Margaret Patrick
Stifel Gets Bullish on the Cannabis Sector in 2020
According to a report by Barron’s on January 7, Stifel analysts expect a rebound in the cannabis sector in the first half of 2020.
Why Trump Has Banned Flavored e-Cigarettes
On January 2, as reported by CNBC, the FDA banned most fruit- and mint-flavored nicotine products. The move aims to reduce teen usage of these products.
CGC Has These Analysts Feeling Pessimistic
Cannabis stocks such as Aurora Cannabis (ACB), Canopy Growth (CGC), Cronos Group (CRON), and Aphria (APHA) were some of the worst-hit stocks in 2019.
Canopy Growth Has Life, Say These Managers
On January 6, Canopy Growth rose 0.74% to 26.02 Canadian dollars on the Toronto Stock Exchange. It was also up 0.90% to $20.08 on the NYSE.
Harvest Health Makes Another Acquisition—What’s New?
On January 2, Harvest Health (HRVSF) agreed to acquire MJardin Group’s 32,000-square-foot cultivation facility in Cheyenne, Nevada, for $35 million.
What Analysts Think about KushCo Holdings in Q1 2020
Of the nine analysts covering KushCo Holdings (KSHB) stock, three analysts rate it as a “strong buy,” and six rate it as a “buy.”
Why MedMen Is Selling Its Assets
Facing a cash crunch, MedMen entered into a definitive agreement with Gotham Green Partners for a $250 million senior secured convertible credit facility.
Illinois Wakes Up to Legalized Recreational Cannabis
On June 25, Illinois governor J.B. Pritzker signed a bill approving marijuana use for everyone over 21 years old. The law became effective on January 1.
Why Wall Street Revised HEXO’s 2020 Estimates
On December 30, Hexo’s (HEXO) share price fell 4.38% to $1.53 on the NYSE. The stock also fell 4.76% to 2.0 Canadian dollars on the TSE.
Cronos’s 2020 Estimates See Revisions in December
On December 27, Cronos Group stock fell 4.17% to 8.97 Canadian dollars on the Toronto Stock Exchange. However, it rose 0.88% on the Nasdaq.
HEXO’s News to Raise $25 Million Spooks Investors
On December 26, HEXO (HEXO) announced a registered direct share offering for raising $25 million from institutional investors.
Is Green Thumb a Good Buy in December 2019?
Green Thumb Industries (GTII) (GTBIF) is a cannabis CPG (consumer packaged goods) company and retailer with headquarters in Chicago, Illinois.
Is GW Pharmaceuticals a Good Buy in December 2019?
GW Pharmaceuticals (GWPH) is a leading player in cannabinoid medicines. The company offers the first FDA-approved plant-derived cannabinoid medicine.
Will Santa Claus Rally Boost Cannabis Stocks?
On December 26, a Santa Claus rally seems to be in full swing. This effect pushed the S&P 500 (SPX) and Nasdaq Composite Index (COMP) to record highs.
Major Institutional Investors Still in Cannabis Sector
It seems that despite the tough market conditions, institutional investors are still keen to invest in the cannabis sector.
Is Acreage Holdings a Good Buy in December?
Acreage Holdings stock has fallen 63.93% YTD in the US OTC exchange. On December 20, the stock closed 77.13% below the 52-week high of $30.
Not All Analysts Believe ACB has Zero Value
On December 19, AltaCorp Capital analyst David Kideckel started coverage for Aurora Cannabis (ACB) with a “Sector Perform” rating.
Why This Fund Manager Wants to Avoid Cannabis Stocks
On December 19, fund manager Norman Levine warned against investing in cannabis stocks and is concerned about the industry’s current lack of profitability.
Is Harvest Health a Good Buy This Month?
This year, Harvest Health & Recreation stock is down 58.01% on US over-the-counter exchanges, and 59.10% on the Canadian Securities Exchange.
HEXO’s Q1 Earnings Were a Bit of a Letdown
HEXO released its first-quarter earnings results on December 16. Subsequently, the stock slid 13.84% from $2.24 on December 13 to $1.93 on December 18.
Is Aphria Expected to Be Profitable in 2020?
Aphria (APHA) stock is down 9.84% year-to-date on the NYSE and 17.18% on the TSE. On December 17, the stock closed 53.15% below its 52-week high.
Is Curaleaf a Good Buy in December?
Curaleaf stock is up year-to-date by 16.67%, but is down 9.19% from $6.09 on November 29 to $5.53 on December 16. Is it a good buy in December?
Is Charlotte’s Web Holdings a Good Buy This Month?
Charlotte’s Web Holdings (CWEB) (CWBHF) stock is currently down 23.64% year-to-date on US over-the-counter exchanges. What’s affected investor sentiment?
The Pros and Cons of Trading a Leveraged Cannabis ETN
The first-ever US leveraged ETN, the MicroSectors Cannabis 2x Leveraged ETN is slated to start trading under the ticker symbol MJO on December 18.
Could Ontario’s Retail Ramp-Up Help Cannabis?
CBC News has reported the Ontario government plans to remove the cap on the number of cannabis shops owned by private retailers in the province.
The Pet Cannabis Industry Is a Lucrative Opportunity
Spending on pet care is gradually rising in the US. As reported by CNBC, Nielsen estimated Americans spent $33 billion on pet food and treats last year.
An Overview of Canopy Growth and Its Brands
Canopy Growth (CGC) announced the US launch of First & Free, its hemp-derived CBD product line. CGC offers softgels, oil drops, and creams.
Valuation Update for Cannabis Stocks in December 2019
The cannabis industry faces regulatory obstacles in Canada and legal risks in international markets. Valuations of these stocks are close to all-time lows.
CGC: How the Future Looks Under Its New CEO
On December 9, Canopy Growth (CGC) appointed David Klein as its new CEO effective January 14. He’s the current CFO of Constellation Brands.
Canopy Growth: A Cannabis 2.0 Update
On December 6, Canopy Growth (CGC) disclosed its rollout plans for Cannabis 2.0 products, such as chocolates, vape pens, vape cartridges, and beverages.
A Look at ACB’s Acquisitions So Far
On November 12, Aurora Cannabis (ACB) chairman Michael Singer shared his plans to rapidly increase the company’s US presence in the next few quarters.
Ontario Cannabis Retail: A Much-Needed Update
As reported by BNN Bloomberg on December 6, Ontario Cannabis Store interim CEO Cal Bricker is confident in Ontario’s readiness for the Cannabis 2.0 launch.
Marijuana in Italy and Aurora Cannabis’s Growth
Italy set up a new parliamentary intergroup for discussing the 2016 citizens’ initiative for cannabis legalization on October 24.
Was CGC a Big Mistake for Constellation Brands?
Canopy Growth (CGC) has seen dizzying ups and gloomy downs in 2019. The stock jumped up by 79.91% from $28.92 on January 2 to $52.03 on April 29.
Marijuana to Treat New Conditions in Minnesota
In August 2020, chronic pain and age-related macular degeneration would be eligible for treatment under Minnesota’s medical marijuana program.
Is ACB Truly a Medical Company at Heart?
On December 2, Aurora Cannabis (ACB) announced approval for one of its cannabis oils under Ireland’s new MCAP (Medical Cannabis Access Programme).
Can the US Cannabis Market Rescue ACB?
Aurora Cannabis (ACB) stock isn’t in the best shape today. As reported by BNN Bloomberg, the company’s CEO, Terry Booth, is justifiably worried.
Can CAUMZ End the Opioid Crisis in Mexico?
Tetra Bio-Pharma plans to partner with Alternavida to develop and market CAUMZ in Mexico. CAUMZ is a therapeutic comprising pure synthetic THC and CBD.
Cronos and Altria’s Deal: Does It Make Sense Now?
Cronos Group, one of the more resilient cannabis stocks, hasn’t escaped the gloom in the cannabis sector. It’s down 37.44% year-to-date on the Nasdaq.
CGC Isn’t Giving Analysts Much to Look Forward To
Canopy Growth (CGC), the largest cannabis company by market cap, has seen better days. Today, the stock is down 30.82% year-to-date on the NYSE.
Our Analysis of ACB’s Latest Financial Results
Once a hot favorite of analysts and investors, Aurora Cannabis (ACB) has become one of the worst-performing cannabis stocks of 2019.
Our Analysis of Aphria’s Fiscal 2020 First-Quarter Results
Aphria (APHA) emerged as one of the stronger cannabis companies in the latest earnings season. Let’s review what’s driven the company’s performance.
What’s the Market Potential for CBD?
The FDA has issued warning letters to 15 companies involved in illegal sales of non-psychoactive CBD products. What’s the legal market’s potential?
Is Jim Cramer Not a Fan of Cannabis Stocks Anymore?
Jim Cramer expressed disappointment with the cannabis industry, claiming it may not be the “incredible opportunity” he thought it was.
Auxly Cannabis Q3 Earnings: Good or Bad News?
Auxly Cannabis (CBWTF) reported its Q3 earnings on November 21. Its stock fell 5.48% and closed at 0.69 Canadian dollars on the Canadian Venture Exchange.
Do New Jersey Voters Want Marijuana Legalized in 2020?
In November, Democratic lawmakers dropped the bill for legalizing recreational marijuana in New Jersey through the Senate.
ACB Focuses on Medical Marijuana Opportunities
Aurora Cannabis’ (ACB) is receiving a lot of flak from analysts and investors. This happened after its disappointing first-quarter performance.
Must-Knows of Fraud Investigations into ACB and CGC
Several prominent law firms have launched investigations into ACB and CGC for potentially violating federal securities law.
Cresco Labs’ Q3 Results Are Coming Up: What to Know
US-based vertically-integrated cannabis player Cresco Labs is set to report its fiscal 2019 third-quarter results on November 26.
California Tightens Noose around Cannabis Industry
California’s legal cannabis market spending will rise from $3.1 billion in 2019 to $7.2 billion in 2024. The market could be $11.0 billion by 2030.
NHS Approves Cannabis Medicines: Market Impact
On November 11, the NHS (National Health Service) approved two cannabis-based medicines, Epidyolex and Sativex, for use in the United Kingdom.
ACB Sees Third-Worst Day in Years: What Analysts Think
On November 18, Aurora Cannabis (ACB) closed at 3 Canadian dollars on the TSX, a 16.43% drop and the third-worst trading day for it in three years.
MedMen Fights for Survival amid Sector Meltdown
On November 15, MedMen (MMEN) (MMNFF) declared an extensive five-year restructuring plan in its attempt to become EBITDA-positive by 2020.
Top 5 Reasons Why Cannabis Earnings Disappointed
There seems to be no end to the cannabis sector’s woes. Several prominent cannabis players reported disappointing results in the latest earnings season.
Aurora Cannabis: Good or Bad News for Its Q1 Earnings?
After Aurora Cannabis’s Q1 earnings release on Thursday, its stock closed at $3.29 on the NYSE, 7.32% lower than the previous day.
Canopy Growth’s Q2 Earnings: Good or Bad News?
Canopy Growth reported its second-quarter earnings results today. It’s already down 16.07% on the day and is trading at 20.52 Canadian dollars on the TSE.
Charlotte’s Web: Are Its Q3 Earnings Good or Bad News?
After Charlotte’s Web reported its Q3 earnings yesterday, it closed at 12.28 Canadian dollars on the TSE, 7.53% lower than its previous closing price.
Cronos Group’s Q3 Earnings: Good or Bad News?
After Cronos Group (CRON) reported its third-quarter earnings results yesterday, its stock closed at 10.40 Canadian dollars on the Toronto Stock Exchange.
Why ACB’s Upcoming Earnings Aren’t Exciting Analysts
Aurora Cannabis (ACB) will be announcing its results for the first quarter of fiscal 2020 on November 14, and analysts aren’t confident in its performance.
Why Analysts Seem Pessimistic about CGC’s Earnings
Canopy Growth (CGC) is set to announce its fiscal 2020 second-quarter results on November 14. Here’s what analysts expect.
MKM Partners Downgrades ACB and CGC
As noted by MKM Partners, yesterday Aurora Cannabis (ACB) fell by 4.97% and closed at $4.78 Canadian dollars. Also, Canopy Growth (CGC) fell by 5.19%
Illegal Vape Creates Opportunity for Legal Cannabis
Prohibition Partners expects that by 2024, the legal cannabis market could reach $103.9 billion and the medical cannabis market could reach $62.6 billion.
Aurora Cannabis: Can It Boost the Industry in Q1?
Canada-based medical and recreational cannabis company, Aurora Cannabis (ACB) will report its Q1 fiscal 2020 results on November 14.
Cronos Group’s Q3 Earnings: What to Expect
Analysts expect Cronos Group to report revenue of $14.62 million Canadian dollars in fiscal Q3 2019. This implies a YoY (year-over-year) rise of 288.74%.
Aurora Cannabis Runs Mexico’s Cannabis Market
Legal cannabis in Mexico is going through several twists and turns. The country first allowed medical marijuana in June 2017.
Why Jason Mann Wants to Bypass Organigram
Yesterday, Organigram (OGI) closed at a 124.63% discount to its consensus target price of 10.49 Canadian dollars. Four analysts rate OGI as a “strong buy.”
Charlotte’s Web: November Price Target Update
Charlotte’s Web Holdings has fallen 15.44% on the Toronto Stock Exchange. Its stock has dropped 43.58% on the TSE since its Q2 earnings on August 14.
Aurora Cannabis: Convertible Debentures for March 2020
Aurora Cannabis has had a rough 2019. Its stock has slid 30.46% YTD on the TSE (Toronto Stock Exchange) and by 24.19% on the NYSE.
Aurora Cannabis Stock Has Disappointed this Year
Aurora Cannabis stock (ACB) has definitely not lived up to investors’ expectations in 2019. The stock is down 30.61% to 4.92 Canadian dollars on the TSE.
What Analysts Expect from Canopy Growth’s Revenues
Canopy Growth (CGC) is set to release its fiscal 2020 second-quarter earnings results on November 14. Let’s take a look at the word on Wall Street.
All You Need to Know about Aphria’s Capacity Expansion
On November 4, Aphria (APHA) announced the receipt of a cultivation license from Health Canada for its Aphria Diamond cannabis greenhouse facility.
What to Expect from IIPR’s Earnings for Q3
Innovative Industrial Properties (IIPR) is scheduled to release its Q3 earnings results on November 6. Find out what cannabis investors can expect.
What Rootstock Cloud ERP Means for Aphria
Rootstock Software implemented its Cloud ERP for Aphria (APHA). This solution would improve Aphria’s product traceability from “seed to sale.”
Here’s What GMP Says about Curaleaf
Curaleaf Holdings (CURA) (CURLF) had a great week. On October 30, GMP Securities analyst Robert Fagan restated the “Buy” rating.
CGC, ACB, and CRON Have Fallen from Their Peaks
Canopy Growth (CGC), Aurora Cannabis (ACB), and Cronos Group (CRON) closed at year-to-date discounts of 33.43%, 32.97%, and 30%, respectively, yesterday.
Why Canopy Growth Stock Has Been a Disappointment
Yesterday, Canopy Growth (CGC) closed at 26.52 Canadian dollars, 1.49% lower than Tuesday’s closing price. CGC is trading 5.27% higher than its 52-week low.
Marijuana in Florida: Five Things You Should Know
Florida is the second-fastest adopter of medical marijuana. The state reports an average increase of 609 medical marijuana patients on a daily basis.
Canopy Growth’s Q2 Earnings: What to Expect
Canada-based diversified cannabis and hemp company Canopy Growth is set to report its fiscal 2020 second-quarter results on November 14.
Could Angela Merkel Legalize Cannabis in Germany?
Media reports indicate that Angela Merkel’s party may consider legalizing cannabis in Germany. Medical marijuana has been legal in Germany since 2017.
How ACB May Benefit from US Marijuana Legalization
Marijuana legalization in the US may soon become a reality. Aurora Cannabis has devised an innovative strategy to gain a headstart in the market.
Here’s Bernie Sanders’ Plan to Legalize Marijuana
Bernie Sanders released his plan to legalize marijuana in the US. He pledged to declassify marijuana as a controlled substance in the first 100 days.
Cannabis Sector: Week Ended October 24 in Review
The cannabis sector saw a small rally in the week that ended on October 24. The ETFMG Alternative Harvest ETF (MJ) rose 1.94% in the week.
Cronos Group: Analysts’ Target Prices and Ratings
Cronos Group (CRON) is down 15.59% YTD. Although CRON hasn’t escaped the gloom surrounding the cannabis sector, it has fared better than most of its peers.
Analysts Turn Bearish on Aurora, Other Cannabis Stocks
Analysts are increasingly bearish on cannabis stocks as the US–China trade war brings more uncertainty and volatility to the global market.
Can Aurora Cannabis’s Luck Change with Cannabis 2.0?
This year has been rough for cannabis companies, including Aurora Cannabis (ACB), whose stock is already down 27.82% year-to-date.
How Marijuana Legalization May Boost Florida’s Economy
Right now, medical marijuana is legal in 33 states. Florida is one state that may aggressively push for recreational marijuana legalization in 2020.
Canopy Growth: Analysts’ Target Prices and Ratings
Macro-economic and political uncertainty across the global market have already taken a toll on Canopy Growth stock (CGC) (WEED).
Zenabis Stock Tanked after Operational Update
Despite solid operational performance, Zenabis stock fell 16.18% yesterday. Investors seem concerned about its plans to delay its facility expansion.
Valuation for Cannabis Stocks in October
The cannabis industry is fighting against the ongoing US-China trade war and recessionary worries, which have hurt valuations across the global market.
Cannabis Update: Cowen Cuts Targets for ACB, CGC
The cannabis industry’s woes refuse to die down. Cash-rich companies Aurora Cannabis, Canopy Growth, Aphria, and Cronos Group are also suffering.
E-Cigarette Ban in New York: Impact on Cannabis Sector
The vaping crisis has brought on some twists and turns for the cannabis sector. New York courts are now weighing an e-cigarette ban.
Cannabis 2.0: What Products Can Canadians Expect?
The Cannabis 2.0 era has officially started. Now, Canadians can legally access a host of cannabis-infused products like beverages, vapes, and edibles.
Why HEXO Is Launching a Low-Cost Product
Yesterday, HEXO (HEXO) announced the launch of a lower-priced cannabis brand, Original Stash, priced at $4.49 per gram.
Aurora Cannabis: Preview of Its Cannabis 2.0 Strategy
On Wednesday, Aurora Cannabis gave a preview of its Cannabis 2.0 strategy. The company provided plans for the roll-out of edibles, concentrates, and vapes.
Canopy Growth Acquires Beckley Canopy Therapeutics
On October 15, Canopy Growth (CGC) completed the acquisition of cannabinoid-based research company Beckley Canopy Therapeutics.
Aphria’s Q1 Earnings Call: Key Takeaways
On October 15, Aphria (APHA) reported its earnings results for the first quarter of fiscal 2020, which ended on August 31.
CannTrust Is Up after Falling below $1
Today CannTrust Holdings is trading at $1.30 on the NYSE, 25.60% higher than its last closing price. It’s risen even faster on the Toronto Stock Exchange.
What Legalizing Cannabis Means for Mexico
Mexico is fast approaching its October 23 marijuana legalization deadline. Multiple legalization proposals before parliament are creating confusion.
Aurora Cannabis’s Price Target Cut by 30%
Aurora Cannabis (ACB) stock is currently down 29.23% on the NYSE on a YTD (year-to-date) basis. The company has lost 14.81% of its value since October 1.
More Downgrades for HEXO before Its Q4 Earnings
Hexo Corp. (HEXO) stock is down 26.24% on the NYSE on a year-to-date basis. This cannabis company has lost 33.94% of its value since October 1.